Deborah Wild: Thrilled to See GeneVentiv Selected for The NIH NHLBI Catalyze Program
Deborah Wild, CEO, Executive Board Member, and Leadership Coach, reposted from Damon Race on LinkedIn:
”Thrilled to see GeneVentiv selected for the NIH NHLBI Catalyze Program — a strong endorsement of both the science and our team. The company’s approach to treating all hemophilia A patients with a single gene therapy holds tremendous promise.
As many of you may know, the treatment of hemophilia is very important to me. Happy to be part of the team.”
Damon Race, President and CEO of GeneVentiv Therapeutics, shared on LinkedIn:
”Proud moment for GeneVentiv Therapeutics!
Our team has been selected into the NIH NHLBI Catalyze Program, which will fund the GLP toxicology study required for our IND submission of GENV-HEM — our one-time gene therapy designed to treat all hemophilia A patients, including those with inhibitors.
This highly competitive NIH program is one of the strongest scientific and regulatory signals of confidence a pre-IND company can receive — reflecting both the strength of our data and the rigor of our development plan. By funding the most capital-intensive portion of IND-enabling work, Catalyze support increases capital efficiency, allowing investor funds to focus on valuation-driving activities — including IND preparation, regulatory engagement, and readiness for our Phase I/II clinical trial.
Execution of the GLP toxicology study will follow dose determination from our upcoming canine efficacy and safety study, scheduled to begin in January 2026, with initial data expected in late Q1 2026. Together with our ongoing NHLBI SBIR award, which supports assay development and canine studies, the Catalyze award provides broad, non-dilutive support across efficacy, safety, and regulatory preparation — a rare position for a preclinical gene therapy company.
Grateful for the continued partnership of our scientific, regulatory, and NIH collaborators as we move GENV-HEM toward the clinic and advance our gene-editing program for Pompe disease.
Read the press release here.”
Stay updated with Hemostasis Today.
-
Apr 15, 2026, 12:44Marwa Elnahas: 4Ts Scoring Tool for Heparin – Induced Thrombocytopenia
-
Apr 15, 2026, 12:27Laurent Bertoletti: Joining Global Experts to Improve Thrombosis Care in Cancer for the ICTHIC 16th Edition
-
Apr 15, 2026, 12:13Francesco Antonio Veneziano: JCDD MDPI Calls for Papers on Advances in Thrombosis and Antithrombotic Therapy
-
Apr 15, 2026, 11:05Julius Kyei Baffour: Understanding Thrombophilia Testing and Patient Risk
-
Apr 15, 2026, 09:10Shall I Bleed Less with Age? Just 2 Weeks Until the Webinar – EHC
-
Apr 15, 2026, 08:51Moustafa Abdou: Sutimlimab is Transforming Outcomes in Cold Agglutinin Disease
-
Apr 15, 2026, 04:52Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
-
Apr 15, 2026, 04:06Brenda Pleasant: Insights from the HFA Symposium on Hemophilia Care
-
Apr 15, 2026, 03:43Lexy Halloran: Addressing Diagnostic Inequities in Women with Chronic Conditions